All Blogs
Jan 16, 2025
Johnson & Johnson MedTech Secures CE Mark for Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter; Medtronic Secures CE Mark for BrainSense™ Adaptive Deep Brain Stimulation; Inquis Medical Finalizes Enrollment for U.S. Pivotal Study on Aventus Thrombectomy System for Pulmonary Embolism; First Patient Enrolled in Argon Medical’s CLEAN-PE Study for Novel Pulmonary Embolism Therapy; Sutter Health and GE HealthCare Partner to Revolutionize Patient Care with AI-Driven Imaging Solution; Saluda Medical Closes $100M Financing to Expand Neuromodulation Portfolio
Johnson & Johnson MedTech Announced CE Mark Approval for Dual Energy THERMOCOOL SMARTTOUCHTM SF Catheter, Bolstering Capabilities in Cardiac Arrhythmias Treatment On January 10, 2025, Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, announced the receipt of European CE ma...
Read More...
Jan 15, 2025
The Evolution and Impact of Electronic Health Records (EHRs) in Modern Healthcare
The healthcare industry has undergone a significant transformation over the past few decades, driven in large part by technological advancements. One of the most pivotal innovations in this transformation is the Electronic Health Record (EHR), which has revolutionized how healthcare providers manage patient informa...
Read More...
Jan 14, 2025
Agios’ PYRUKYND SNDA Accepted by FDA for Thalassemia; BridgeBio’s BBO-8520 Gets FDA Fast Track for KRASG12C-Mutated Lung Cancer; Nipocalimab Granted FDA Priority Review for Myasthenia Gravis; Rigel’s R289 Receives FDA Orphan Drug Designation for MDS; Rise Therapeutics Gets FDA IND Clearance for R-5780 in Cancer
FDA Accepts Agios’ SNDA for PYRUKYND in Thalassemia Patients Agios Pharmaceuticals, Inc. announced that the FDA has accepted its supplemental New Drug Application (sNDA) for PYRUKYND® (mitapivat) to treat adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia. The appl...
Read More...
Jan 13, 2025
Bristol Mayer Squibb — The Undisputed Leader in the Molecular Glue Arena
Bristol Myers Squibb stands tall as the undisputed leader in the molecular glue arena, shaping the future of targeted therapies. With its groundbreaking advancements, the company has redefined the potential of molecular glues in oncology, offering innovative solutions that precisely degrade harmful proteins. Bristo...
Read More...
Jan 09, 2025
Roche Secures FDA Clearance for High-Volume Slide Scanner; Pacira Gets 510(k) Approval for Iovera° SmartTip for Chronic Back Pain; ClearCut Presents Clearcoast™ Study Results at San Antonio Breast Cancer Symposium; NanoVibronix Completes UroShield® Pilot Study at University of Michigan; Hologic Finalizes Acquisition of Gynesonics; Movano Health Launches EvieAI Virtual Wellness Assistant.
Roche's Momentum in Digital Pathology Continued With FDA Clearance on its High-Volume Slide Scanner On January 09, 2025, Roche announced that its whole slide imaging system, Roche Digital Pathology Dx, received an additional 510(k) clearance from the United States Food and Drug Administration (FDA). This c...
Read More...
Jan 07, 2025
Chimerix Submits Dordaviprone NDA for Accelerated Approval in Recurrent H3 K27M-Mutant Diffuse Glioma to FDA; NMD Pharma’s NMD670 Receives FDA Orphan Drug Designation for Charcot-Marie-Tooth Disease; Verastem’s Avutometinib NDA Accepted for KRAS Mutant Ovarian Cancer; Capricor Submits BLA for Deramiocel in Duchenne Muscular Dystrophy; Axsome Completes Phase III Trial of AXS-05 for Alzheimer’s Agitation
Chimerix Submits Dordaviprone NDA for Accelerated Approval to FDA for Recurrent H3 K27M-Mutant Diffuse Glioma Chimerix announced the submission of a NDA to the FDA for dordaviprone. The application seeks accelerated approval for the treatment of recurrent H3 K27M-mutant diffuse glioma, a rare and aggressive brai...
Read More...
Jan 08, 2025
The Promise of Big Data in Healthcare: Transforming Treatment and Outcomes
In recent years, the healthcare sector has undergone a major transformation, thanks to the advent of Big Data. The term “Big Data” refers to vast amounts of data—structured and unstructured—that are generated at an incredible speed. This data, when harnessed correctly, has the potential to revolutionize healthcare ...
Read More...
Jan 10, 2025
The Rise of Molecular Glues: Transforming Protein-Protein Interactions into Therapeutic Opportunities
Molecular glues are a groundbreaking class of small molecules that are gaining significant attention in the field of drug discovery. These compounds offer a novel approach to modulating protein function, especially for challenging targets that have been difficult to address using traditional drug discovery methods....
Read More...
Jan 06, 2025
Lilly’s ZEPBOUND Clears Hurdle in Sleep Apnea Treatment
Eli Lilly’s blockbuster weight loss GLP-1 drug ZEPBOUND has received FDA approval to treat obstructive sleep apnea in adults with obesity, alongside diet and exercise. This marks the first FDA-approved medication for obstructive sleep apnea. The approval adds a second indication for ZEPBOUND, following its...
Read More...
Jan 03, 2025
7 Sickle Cell Disease Therapies to Keep an Eye on Post-Pfizer’s OXBRYTA Withdrawal
In September 2024, Pfizer voluntarily withdrew all lots of OXBRYTA for the treatment of SCD in all markets where it was approved. Pfizer is also discontinuing all active voxelotor clinical trials and expanding access programs worldwide. The decision is based on the totality of clinical data, which now indicates tha...
Read More...